-
This is the second in a three-part series about the design and conduct of clinical research.
-
-
Sickle cell disease celebrated its 100th anniversary last year, prompting consideration of what has transpired for those with the disease since its description by Dr. James Herrick in 1910.
-
-
The FDA has approved the first fixed-dose combination product for the treatment of type 2 diabetes and hypercholesterolemia. This tablet combines a dipeptidyl peptidase-4 inhibitor (sitagliptin) and a HMG-CoA reductase inhibitor (simvastatin).
-
In a large randomized trial of healthy men, dietary supplementation with vitamin E (400 IU/day) significantly increased the risk of prostate cancer.
-
In a large community-based cohort of older women, those who self-reported use of multivitamins, vitamin B6, folate, iron, magnesium, zinc, and copper were more likely to die than those who do not. Calcium use, however, was associated with reduced risk.
-
The presence of any observed hostility at baseline was associated with a two-fold increased risk of incident ischemic heart disease over a 10-year period of observation.
-
The lead II rhythm strip shown above was obtained from a woman with new-onset palpitations. How would you interpret this tracing? How certain are you of your answer? Clinically what would you do?
-
The decode data (diabetes epidemiology Collaborative Analysis of Diagnostic Criteria in Europe) indicated that all-cause mortality, as well as cardiovascular (CV) events, were better predicted by postprandial glucose (PPG) than fasting blood glucose (FPG).